Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T, KEYNOTE-564 Investigators

Open source

DOI: 10.1056/nejmoa2106391
Published: 2021 Aug 19
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2106391,
  title = {Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.},
  author = {Choueiri TK and Tomczak P and Park SH and Venugopal B and Ferguson T and Chang YH and Hajek J and Symeonides SN and Lee JL and Sarwar N and Thiery-Vuillemin A and Gross-Goupil M and Mahave M and Haas NB and Sawrycki P and Gurney H and Chevreau C and Melichar B and Kopyltsov E and Alva A and Burke JM and Doshi G and Topart D and Oudard S and Hammers H and Kitamura H and Bedke J and Perini RF and Zhang P and Imai K and Willemann-Rogerio J and Quinn DI and Powles T and KEYNOTE-564 Investigators},
  year = {2021},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2106391},
  url = {https://doi.org/10.1056/nejmoa2106391}
}

RIS

TY  - JOUR
TI  - Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
AU  - Choueiri TK
AU  - Tomczak P
AU  - Park SH
AU  - Venugopal B
AU  - Ferguson T
AU  - Chang YH
AU  - Hajek J
AU  - Symeonides SN
AU  - Lee JL
AU  - Sarwar N
AU  - Thiery-Vuillemin A
AU  - Gross-Goupil M
AU  - Mahave M
AU  - Haas NB
AU  - Sawrycki P
AU  - Gurney H
AU  - Chevreau C
AU  - Melichar B
AU  - Kopyltsov E
AU  - Alva A
AU  - Burke JM
AU  - Doshi G
AU  - Topart D
AU  - Oudard S
AU  - Hammers H
AU  - Kitamura H
AU  - Bedke J
AU  - Perini RF
AU  - Zhang P
AU  - Imai K
AU  - Willemann-Rogerio J
AU  - Quinn DI
AU  - Powles T
AU  - KEYNOTE-564 Investigators
PY  - 2021
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2106391
UR  - https://doi.org/10.1056/nejmoa2106391
ER  -

APA

TK, C., P, T., SH, P., B, V., T, F., YH, C., J, H., SN, S., JL, L., N, S., A, T., M, G., M, M., NB, H., P, S., H, G., C, C., B, M., E, K., A, A., JM, B., G, D., D, T., S, O., H, H., H, K., J, B., RF, P., P, Z., K, I., J, W., DI, Q., T, P., & Investigators, K. (2021). Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2106391

Source records

pubmed · retrieved 2026-09-26T10:02:13.941Z